BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 108.7% based on the discounted cash flow analysis.
| Market cap | $2.43 Billion |
|---|---|
| Enterprise Value | $2.40 Billion |
| Dividend Yield | $1.28 (-) |
| Earnings per Share | $0.43 |
| Beta | 0.38 |
| Outstanding Shares | 375,000,000 |
| P/E Ratio | -2.21 |
|---|---|
| PEG | -2.97 |
| Price to Sales | 0.3 |
| Price to Book Ratio | -2.11 |
| Enterprise Value to Revenue | 0.3 |
| Enterprise Value to EBIT | 1.12 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.36 |
| Debt to Equity | -0.49 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1968▼ 172.32% |
|---|---|
| Total Calls | 1,362,000▼ 27.68% |
| Total Puts | 268,000▼ 92.59% |
Holdings and activity of institutional investors.
| Ownership % | 3.13%▼ 59.27% |
|---|---|
| Total Invested | $57.71M▼ 95.44% |
| Investors Holding | 88▼ 157.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...